NUNZ OTC
Nunzia Pharmaceutical Company
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$78M
-198391.9% ▼
Net Income
-$78M
+22.7% ▲
EPS (Diluted)
$-0.26
+25.7% ▲
EBITDA
-$78M
-763.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13K | $27K | $34K | $16K | $78M |
| Operating Expenses | $13K | $27K | $34K | $16K | $78M |
| Operating Income | -$13K | -$27K | -$34K | -$39K | -$78M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $92M | $2K |
| Income Before Tax | -$13K | -$19K | -$34K | -$101M | -$78M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$13K | -$19K | -$34K | -$101M | -$78M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.00 | $-0.00 | $-0.00 | $-0.35 | $-0.26 |
| EBITDA | -$13K | -$27K | $138K | -$9M | -$78M |
| Shares Outstanding | 147M | 147M | 253M | 285M | 305M |